Explore

Trendline Trendline
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies

EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies

EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
Trendline Trendline
EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress

EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress

EyePoint Reports Increased Losses Amid DURAVYU Phase 3 Trials Progress
Trendline Trendline
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
Trendline Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Trendline Trendline
GeneDx Reports Strong Q1 2026 Financial Results and Updates Outlook

GeneDx Reports Strong Q1 2026 Financial Results and Updates Outlook

GeneDx Reports Strong Q1 2026 Financial Results and Updates Outlook
Trendline Trendline
GeneDx Reports Q1 2026 Financial Results and Updates Outlook

GeneDx Reports Q1 2026 Financial Results and Updates Outlook

GeneDx Reports Q1 2026 Financial Results and Updates Outlook
Trendline Trendline
Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches

Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches

Vanda Pharmaceuticals Reports Q1 2026 Financial Results Highlighting Growth and New Product Launches
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Expansion Plans
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
SOPHiA GENETICS Reports Strong Q1 2026 Growth Driven by AI-Powered Precision Medicine

SOPHiA GENETICS Reports Strong Q1 2026 Growth Driven by AI-Powered Precision Medicine

SOPHiA GENETICS Reports Strong Q1 2026 Growth Driven by AI-Powered Precision Medicine
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark